CBT Advisors is an international strategic consultancy supporting the US and European biotech industries, the life science venture capital industry and the technology transfer field. We provide specialized services in investor pitches, communications strategy and business strategy based on our deep understanding of the life science financing market. CBT Advisors has delivered market and competitive analyses as well as positioning and exit strategies to clients in both large and small biotech as well as the pharmaceutical industry in areas ranging from biopharmaceuticals to tools to small molecule therapeutics and medical devices. Here are some ways in which CBT (www.cbtadvisors.com) has recently assisted both companies and investors:

Strategic marketing plans, corporate communications and marketing pitches to investors.
Recent cases:
• Provided Avontec, a Munich-based therapeutics company, with a comprehensive review and rewriting of company presentation materials. Site launched at www.avontec.com
• Assisted Immatics GmbH, a Germany-based therapeutics company, with investor meetings that helped lead to a Series B financing of $52 million in under 5 months
• Wrote or co-wrote articles for publication in top journals including Nature Reviews Drug Discovery
• Provided positioning strategies, exit strategies, marketing materials and business plans for more than ten US, European and Asian companies
• Assisted several existing and new VC funds in telling their stories to potential investors. One fund closed on over $250 million in 2005, another announced a closing of $260 million in 2007.

Corporate strategy, market analysis and communications strategy.
Recent cases:
• Assessed strategic options and made recommendations for $500 million public science-driven biotech company regarding an exciting new technology
• Prepared term sheet and planned negotiation strategy with VC-backed Boston-area biotech company for in-licensing and out-licensing of therapeutic products
• Performed market analysis and physician interviews regarding novel vasopressin antagonist and its potential for treating congestive heart failure
• Performed market analysis and physician interviews regarding novel therapies for autoimmune disease for private US biotech company and neurological disease for public US biotech company
• Assessed communications strategy for top-tier VC-backed DNA tools startup including formulating and rehearsing management responses to issues of potential public concern

CBT has been able to exceed client expectations in many ways after serving more than 15 clients a year in the United States and Europe since 2004. Selected CBT clients, past and present:

Contact sdickman@cbtadvisors.com, Tel: +1-617 758 4181.

back to top

Edwards Angell Palmer & Dodge LLP has been at the forefront of life sciences for more than 20 years representing 150 public and private life sciences companies and some of the premier venture capital and investment banking firms that invest in that industry. Large pharmaceutical companies and emerging biotech companies turn to us on a variety of issues, including intellectual property, licensing and collaboration, mergers and acquisitions, capital raising, FDA counseling and international partnering. Our more than 100 lawyers, many of whom have advanced degrees, represent companies in all stages of development from true start-ups, to VC finance development stage companies, to publicly traded industry leaders.

www.eapdlaw.com

back to top

Your Global Capitalization Partner
Katan Associates is a global advisory organization that provides capitalization strategies and a broad range of services to high growth, highly innovative life sciences companies, biotechnology firms and biomedical enterprises.

Based in the world’s leading centers for biotechnology and biomedicare, Katan Associates brings together specialists from a diverse range of corporate and commercial backgrounds to advise firms on long term growth and capitalization solutions.

Katan Associates focuses on five core areas of specialization in helping firms achieve their business growth.

• Strategy Formulation
• International Business Development
• Investment Banking / Venture Capital
• Government and Industry Advisory
• Mergers and Acquisitions

Katan provides businesses and management teams with the tools and the infrastructure to grow and expand their business.

To find out more, please visit our website at www.katanassociates.com

Or contact Seth Yakatan, Partner, at 323.356.6321 or seth@katanassociates.com

back to top

Lexicon Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease.  The company is using its proprietary gene knockout technology to systematically discover the physiological and behavioral functions of 5,000 pharmaceutically relevant genes.  Through this program, known as the Genome5000™ program, Lexicon has discovered more than 100 promising drug targets and created a broad pipeline of clinical and preclinical programs in the therapeutic areas of cardiology, gastroenterology, immunology and oncology, metabolism, neurology and ophthalmology.   

Drug Development Programs
Lexicon plans to advance 10 drug candidates into human clinical trials through 2010.  This strategic initiative is referred to as the 10TO10 program and is a natural evolution of the company’s target identification efforts.  Lexicon has advanced three drug candidates into human clinical trials, filed an Investigational New Drug (IND) application for a fourth candidate, has one additional program in preclinical development, and a number of additional programs in various stages of preclinical research.  The company’s lead program, LX6171, is in Phase 2 clinical trials for the treatment of cognitive disorders.  Lexicon’s drug pipeline consists of small molecule and biologic drug candidates, a fact that diversifies the company’s approach to drug discovery and development.  All of Lexicon’s drug targets have been identified internally as part of its Genome5000 program.

Strategic Alliances
To advance the development and commercialization of its programs, Lexicon is working both independently and through collaborators which include Bristol-Myers Squibb Company, Genentech, Inc. and N.V. Organon.

www.lexpharma.com

back to top

Yorkville Advisors, LLC is the investment manger to a dedicated private investment fund that provides innovative financing solutions to public and private companies (ÒIssuersÓ) worldwide. Yorkville works closely with management to design custom-tailored, alternative financing structures that meet the Issuer's capital needs and corporate goals. Yorkville has structured transactions with numerous companies listed in the US, UK, Australia, Brazil, Singapore, Malaysia, India, Italy and Hong Kong. Yorkville seeks to structure investments using convertible and straight debt, bridge loans, convertible or straight equity and equity lines while making investments in a broad range of transactions, including late-stage venture, growth and mature enterprises, control and non-control transaction, special situations and management or leveraged buyouts.

www.yorkvilleadvisors.com

back to top